| GTO ID | GTC1856 |
| Trial ID | NCT03412877 |
| Disease | Ovarian Cancer | Genitourinary Cancer | Lung Non-Small Cell Carcinoma | Multiple Myeloma | Neuroendocrine Tumor | Breast Cancer |
| Altered gene | Neoantigen |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Neoantigen TCR-T cells |
| HLA | HLA-A*02:01 |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer |
| Year | 2018 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 180049|18-C-0049 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||